XERS:NSD-Xeris Pharmaceuticals Inc (USD)

COMMON STOCK | Biotechnology |

Last Closing

USD 5.58

Change

0.00 (0.00)%

Market Cap

USD 0.65B

Volume

3.27M

Analyst Target

USD 11.00
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-03-30 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
VRTX Vertex Pharmaceuticals Inc

N/A

USD 126.52B
REGN Regeneron Pharmaceuticals Inc

N/A

USD 69.68B
ARGX argenx NV ADR

N/A

USD 37.97B
ALNY Alnylam Pharmaceuticals Inc

N/A

USD 31.94B
ONC BeiGene, Ltd.

N/A

USD 28.70B
RPRX Royalty Pharma Plc

N/A

USD 19.31B
SMMT Summit Therapeutics PLC

N/A

USD 14.57B
UTHR United Therapeutics Corporatio..

N/A

USD 14.37B
INCY Incyte Corporation

N/A

USD 14.22B
MRNA Moderna Inc

N/A

USD 13.74B

ETFs Containing XERS

BBC Virtus LifeSci Biotech Cl.. 1.65 % 0.79 %

N/A

USD 0.01B
ETLI:XETRA L&G Pharma Breakthrough U.. 0.00 % 0.00 %

N/A

USD 0.02B

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 64.60% 96% N/A 97% N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 64.60% 96% N/A 97% N/A
Trailing 12 Months  
Capital Gain 152.49% 97% N/A 97% N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 152.49% 97% N/A 97% N/A
Trailing 5 Years  
Capital Gain 186.15% 90% A- 86% B+
Dividend Return N/A N/A N/A N/A N/A
Total Return 186.15% 90% A- 85% B
Average Annual (5 Year Horizon)  
Capital Gain 4.60% 57% F 54% F
Dividend Return 4.60% 57% F 50% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 56.75% 57% F 33% F
Risk Adjusted Return 8.11% 59% D- 42% F
Market Capitalization 0.65B 77% C+ 67% D+

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.